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fate administration. One woman of group 1 developed sev-
eral episodes of a third-degree atrioventricular block within 
the first 3 days after fetal surgery. Lethargy was found in all 
women during magnesium sulfate therapy. No maternal 
side effects were found under atosiban.  Discussion: The use 
of atosiban resulted in an almost identical short-term uterine 
outcome without any serious maternal complications as 
seen when magnesium sulfate was given. Thus, the authors 
suggest using atosiban instead of magnesium sulfate in the 
context of open fetal surgery.  © 2017 S. Karger AG, Basel 
 Introduction 
 Open fetal myelomeningocele (MMC) repair is an in-
novative therapeutic option in selected cases  [1] since the 
results of the MOMS trial showed that prenatal repair 
produces better outcomes than postnatal repair  [2] . How-
ever, one of the main concerns after open fetal surgery is 
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 Abstract 
 Introduction: To compare tocolysis with magnesium sulfate 
versus atosiban regarding the occurrence of short-term pre-
term labor and maternal side effects during and after open 
fetal myelomeningocele (MMC) repair.  Material and Meth-
ods: A prospective nonrandomized cohort study was per-
formed including 30 fetal MMC cases. The first 15 cases 
(group 1) received magnesium sulfate according to the 
MOMS protocol. In the following 15 cases (group 2), magne-
sium sulfate was substituted by atosiban. Chorioamniotic 
membrane separation (CMS), premature prelabor rupture of 
the fetal membranes (PPROM), preterm delivery <3 weeks 
after fetal MMC repair, and maternal complications due to 
the tocolytic medication were the major endpoints.  Results: 
In both groups, one CMS but no PPROM was diagnosed <3 
weeks after fetal MMC repair. One patient of group 2 deliv-
ered <3 weeks after fetal MMC repair because of an intraop-
erative placental abruption at 25 weeks. All women of group 
1 showed an electrolyte imbalance during magnesium sul-
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potentially deleterious preterm labor. Beside cervical dil-
atation, increased uterine contractility and rupture of the 
chorioamniotic membranes are factors inducing preterm 
labor  [3, 4] . To minimize the risk of an increased uterine 
contractility after open fetal MMC repair, tocolytics are 
applied. The tocolytics used in the MOMS trial were high 
doses of magnesium sulfate and indomethacin periopera-
tively followed by nifedipine.
 The aim of this paper was to compare two different 
tocolytic regimens, namely magnesium sulfate and ato-
siban, with regard to short-term preterm labor and ma-
ternal side effects. Chorioamniotic membrane separa-
tion (CMS), premature prelabor rupture of the fetal 
membranes (PPROM), and preterm deliveries <3 weeks 
after fetal MMC repair as well as maternal complications 
due to the tocolytic medication were the major end-
points.
 Material and Methods 
 From December 2010 till December 2015, a total of 30 fetal 
MMC repair operations were performed at the Zurich Center for 
Fetal Diagnosis and Therapy (www.swissfetus.ch). In this prospec-
tive nonrandomized cohort study, all patient data were entered in 
our fetal MMC repair database. The usual maternal and fetal stem 
data as well as maternal and fetal outcomes were documented in 
detail. The study was conducted in accordance with the approval 
of the ethics commission Zurich (KEK-ZH No. 2015-0172).
 Inclusion criteria for maternal-fetal surgery were singleton 
pregnancy, MMC with the upper level located between T1 and S1, 
evidence of hindbrain herniation, gestational age (GA) of 19–25.9 
weeks, normal karyotype, maternal age of at least 18 years, and 
maternal BMI <40. Major exclusion criteria were additional fetal 
malformations unrelated to MMC, severe kyphosis >30°, short 
cervix or previous preterm birth, placenta previa, former placental 
abruption, maternal HIV or hepatitis B/C positivity, uterine ab-
normality (big or multiple fibroids), previous hysterotomy in the 
active uterine segment, psychosocial problems, and any other con-
traindication for major surgery. Women with a fetal MMC re-
ferred to our center were evaluated in a standardized way by so-
nography and a fetal MRI prior to comprehensive prenatal coun-
seling. If the patient qualified for fetal MMC repair, written 
informed consent was obtained, and the fetal operation was sched-
uled to occur between 22–26 gestational weeks (GW). The fetal 
MMC repair was performed by fetal surgeons according to stan-
dardized operative techniques as reported in the MOMS trial. Fetal 
monitoring (fetal heart rate and myocardial contractility) was as-
certained by continuous sterile ultrasound throughout the opera-
tion. Uterine relaxation was monitored clinically during the entire 
intervention. Postoperatively, contractions were monitored clini-
cally as well as via cardiotocography (CTG) in a standardized fash-
ion.
 Perioperative tocolysis was performed with two different regi-
mens, one based on magnesium sulfate (group 1), the other based 
on atosiban (group 2). These two groups were then compared.
 Group 1 
 The first 15 cases (cases 1–15) were managed by a modified 
MOMS trial protocol during the first 36 h: they received 100–200 
mg indomethacin perioperatively, 6 g of magnesium sulfate at the 
time of the hysterotomy closure as an intravenous bolus over 20 
min followed by a continuous magnesium sulfate infusion of 4 g/h 
for 2 h and 3 g/h thereafter for 6 h. If there was no evidence of sig-
nificant uterine irritability or contractions, the magnesium sulfate 
dose was gradually decreased to 2–2.5 g/h with a target plasmatic 
magnesium level of 3.0–3.3 mmol/L (=7.3–8 mg/dL). After the first 
24 h, magnesium sulfate was stopped and the patient received oral 
nifedipine 120 mg/day till delivery. In deviation from the MOMS 
protocol, atosiban, a selective oxytocin receptor antagonist, or 
hexoprenaline, a betamimetic agent, served as emergency medica-
tion to abolish contractions (both substances not approved by the 
Food and Drug Administration [FDA] in the US). One cycle of 
atosiban included a 6.75-mg i.v. bolus followed by 18 mg/h over 
3 h and 6 mg/h for the following 45 h. Hexoprenaline was admin-
istered at a dose of 3–18 μg/h dependent on contractions. Finally, 
patients received  Bryophyllum pinnatum tablets 50% 4 × 2 p.o./
day.
 Group 2 
 The subsequent 15 cases (cases 16–30) received 100–200 mg 
indomethacin perioperatively. Instead of magnesium sulfate, ato-
siban was administered intraoperatively with a 6.75-mg bolus i.v. 
followed by 18 mg/h over 3 h and 6 mg/h for the following 45 h 
(=1 cycle of atosiban). Additionally, nifedipine 120 mg p.o./day 
was given 24 h after the fetal operation till delivery. Dependent on 
uterine contractions, the patient received further atosiban cycles 
or hexoprenaline in addition to  Bryophyllum pinnatum tablets 
50% 4 × 2 p.o./day.
 After fetal MMC repair, all women were monitored in an in-
tensive care unit (ICU) for 2 days. Analgetic management includ-
ed an epidural analgesia for 3–5 days, paracetamol 4 × 1 g i.v./day, 
and tramadol 50–200 mg p.o./day if necessary. During the surveil-
lance phase on the ICU, contractions were continuously registered 
by tocography using the IntelliSpace Perinatal information system 
(Philips AG Healthcare, Zurich, Switzerland) and fetal heart rate 
was checked by doptone (<24 GW) or CTG (>24 GW) 3 times per 
day. Ultrasonography was performed at least twice a day to check 
the amount of amniotic fluid, hematoma formation, or CMS and 
fetal perfusion. After transfer to our prenatal unit, contractions 
were monitored by tocography (<24 GW) or CTG (>24 GW) twice 
a day. Ultrasonography was conducted once a week. All operated 
women were recovered for a minimum of 4 weeks at our institu-
tion.
 CMS, PPROM, and preterm deliveries within 3 weeks after fe-
tal MMC repair as well as maternal complications from tocolysis 
were the major endpoints.
 Statistical analysis was performed using the statistical software 
package SPSS version 22.0 (IBM, SPSS Inc., Chicago, IL, USA). 
Quantitative data are presented as mean ± standard deviation (SD) 
or medians with minimum and maximum values. The results of 
categorical variables are given as percentages. Mann-Whitney U 
test and χ 2 tests were used as appropriate. A  p value <0.05 was con-
sidered statistically significant.
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 Results 
 Maternal characteristics of the study population are 
presented in  Table 1 . In both groups, one or no CMS or 
PPROM was diagnosed <3 weeks after fetal MMC repair 
( Table 2 ). GA at birth after open fetal MMC repair was 
comparable in both groups ( Table 3 ).
 One patient (7%) of group 2 delivered <3 weeks after 
fetal MMC repair. Here, an intraoperative placental ab-
ruption occurred towards the end of the operation. This 
event was unrelated to tocolysis. Whether it took place 
due to massive amnioreduction or uterine manipulation 
during fetal positioning remains speculative. Therefore, 
the fetus was delivered during the intervention at GA 25.3 
weeks. The baby girl finally went home with no major 
 Table 1. Characteristics of patients who underwent fetal myelomeningocele repair at the Zurich Center for Fetal 
Diagnosis and Therapy (group 1 received tocolysis with magnesium sulfate and group 2 atosiban without mag-
nesium sulfate)
Group 1
(cases 1 – 15)
Group 2
(cases 16 – 30)
p
Gestational age at evaluation, weeks 22.2 ± 2.1 23.2 ± 1.9 0.17
Gestational age at fetal surgery, weeks 24.2 ± 1.0 24.9 ± 0.8 0.03
Maternal age, years 29.9 ± 4.9 30.0 ± 4.8 0.87
Nulliparous 9 (60) 9 (60) 1
Ethnicity 0.35
Caucasian 13 (87) 14 (93)
Black 1 (7)
Hispanic 1 (7)
Others 1 (7)
Body mass index 26.1 ± 4.3 28.1 ± 5.6 0.3
Current smoker 0 0 1
Married or living with partner 14 (93) 15 (100) 0.31
Positive family history of spina bifida 0 0 1
Previous uterine surgery 1 (7) 1 (7) 1
Cervical length, mm 42.9 ± 5.3 40.8 ± 4.9 0.31
Anterior placenta 8 (53) 10 (67) 0.46
 Values are means ± SD or n (%). The only significant difference between group 1 and 2 was gestational age at 
surgery (p = 0.03).
 Table 2. Rates of chorioamniotic membrane separation (CMS), premature prelabor rupture of the fetal membranes 
(PPROM), and delivery <3 weeks after open fetal myelomeningocele repair under tocolysis with magnesium 
sulfate (group 1) or atosiban without magnesium sulfate (group 2)
Group 1
(cases 1 – 15)
Group 2
(cases 16 – 30)
p
CMS <3 weeks after operation, n (%)
Gestational age at diagnosis of CMS, weeks
1 (7)
24.0 (directly 
postoperatively)
1 (7)
25.9 (1.5 weeks after 
operation)
1
PPROM <3 weeks after operation, n (%) 0 0 1
Birth <3 weeks after operation, n (%)
Gestational age at birth, weeks
0 1 (7)*
25.3*
0.31
* Case with an intraoperative placental abruption and delivery directly after fetal myelomeningocele repair.
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neurologic deficit and no prematurity-associated sequel-
ae except for bilateral retinopathy that responded well to 
laser therapy. This case of an intraoperative placental ab-
ruption was excluded for the comparison of the tocolyt-
ics. In both groups, postoperative contractions were suc-
cessfully suppressed.
 All women of group 1 showed an oftentimes marked 
electrolyte imbalance during the magnesium sulfate ad-
ministration with serum levels of 3.2 ± 0.4 mmol/L. All 
women had a hypocalcemia with total calcium serum lev-
els of 1.5 ± 0.2 mmol/L. One woman with the lowest cal-
cium level of 1.13 mmol/L – her maximal magnesium 
level was 3.0 mmol/L – showed carpopedal spasms which 
needed treatment with calcium i.v. Potassium or sodium 
serum levels of these women were 3.4 ± 0.3 mmol/L or 
137 ± 1.9 mmol/L, respectively. Transient hypokalemia 
or hyponatremia was present in 5 (33%) or 6 (40%) wom-
en, respectively. Objectively, severe lethargy was found in 
all women during magnesium sulfate therapy. Subjective-
ly, all patients complained about feeling severely ill for 
2–3 days (“like run over by a truck”).
 The last patient of group 1 (case 15) developed 4 short 
episodes of a third-degree atrioventricular block (AV 
block III°) within the first 3 days after fetal surgery, so that 
she was monitored for a total of 8 days in the ICU. Her 
maximum magnesium blood level was 3.05 mmol/L. Af-
ter the first AV block III° episode, occurring 11 h after 
fetal surgery, magnesium sulfate was stopped. Phosphate 
and calcium were substituted in order to correct her elec-
trolyte imbalance. All further assessments including 
echocardiography, 48 h-ECG, and heart MRI for exclu-
sion of an arrhythmogenic right ventricular cardiomy-
opathy showed normal results. Further course of preg-
nancy was uneventful till delivery after PPROM with con-
tractions at GA 32.7 weeks.
 The women of group 1 did not receive statistically sig-
nificantly more indomethacin (117 ± 31 mg) when com-
pared with the women of group 2 (100 ± 0 mg) ( p = 0.23).
 There were no side effects whatsoever attributable to 
atosiban therapy. All women of group 2 were completely 
awake within the first hours after open fetal MMR repair 
and none uttered similar complaints as those of the pa-
tients of group 1.
 Discussion 
 This study compared magnesium sulfate with atosiban 
for perioperative tocolysis in the context of open fetal sur-
gery for spina bifida. The main endpoints of this prospec-
tive cohort study were tocolytic efficacy and maternal side 
effects.
 In the global picture, we found similar rates of CMS, 
PPROM, and delivery within 3 weeks after fetal MMC 
repair in both groups, indicating that both tocolytic regi-
mens are similar if not identical regarding uterine effi-
cacy.
 Yet, under magnesium sulfate, all women exhibited an 
oftentimes marked electrolyte imbalance, lethargy, and 
feelings of being sick. One woman developed severe and 
potentially dangerous episodes of an AV block III° within 
the first 3 days after fetal surgery, almost certainly trig-
gered by a magnesium-induced marked electrolyte im-
balance, since other arrhythmogenic factors could be 
ruled out. In sharp contrast, all patients in the atosiban 
group were completely free from any measurable side ef-
fects, and they uttered no feelings of being sick whatso-
ever.
 Maternal side effects from treatment with high-dose 
magnesium sulfate for preterm labor are well known  [5] . 
Of 456 women, 417 (91%) experienced side effects, with 
severe symptoms in 24 women (5.3%). Of these 24 wom-
en, 23 (5% of the total cohort) had pulmonary edema and 
one developed tachyarrhythmia while on magnesium. All 
were transferred to the ICU  [5] . Also, one should be aware 
of possible cardiopulmonary drug interactions among 
pregnant women who receive magnesium sulfate. Thus, 
cardiac arrest was documented in 5 of 53 (9.3%) women 
who additionally received furosemide  [6] . In our case of 
an AV block III°, no additional drug interaction could be 
identified, but the electrolyte imbalance was considered 
to be the trigger as other arrhythmogenic causes were ab-
sent.
 Table 3. Gestational age at birth after open fetal myelomeningocele 
repair under tocolysis with magnesium sulfate (group 1) or ato-
siban without magnesium sulfate (group 2)
Group 1
(cases 1 – 15)
Group 2
(cases 16 – 30)
p
Gestational age at birth, weeks 35.9 ± 1.4 35.2 ± 3.2 0.43
<30 weeks, n (%) 0 1 (7)* 0.31
30 – 34 weeks, n (%) 4 (27) 3 (20) 0.67
35 – 36 weeks, n (%) 5 (33) 6 (40) 0.71
≥37 weeks, n (%) 6 (40) 5 (33) 0.71
* Case with an intraoperative placental abruption and delivery 
directly after fetal myelomeningocele repair.
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 As the best maternal safety profile was shown for ato-
siban when compared with magnesium sulfate, beta-mi-
metics, indomethacin, or calcium channel blockers  [7, 8] , 
and based on our own experience reported here, we 
strongly recommend that magnesium sulfate should not 
be used as a short-term tocolytic anymore. Instead, atosi-
ban seems to be the most appropriate choice.
 In contrast to Europe, there is no approved tocolytic 
in the US to treat preterm labor. Thus, Klauser et al. in 
2014  [9] stated that clinicians in the US should use the 
medication that yielded the best results with the lowest 
rate of maternal or neonatal side effects. Elliot and Mor-
rison in 2013  [10] explicitly criticize that the FDA has 
blocked the use of atosiban in the US although it remains 
available, and is routinely used, in the rest of the world.
 The use of magnesium sulfate as a tocolytic agent is 
still controversial  [7] . In a Cochrane analysis on giving 
birth within 48 h after trial entry, no significant differ-
ences were seen between women who received magne-
sium sulfate for tocolysis and women who did not  [11] . 
Furthermore, in the group treated with magnesium sul-
fate compared to women receiving antenatal placebo or 
no alternative tocolytics, a minimally increased risk of fe-
tal, neonatal, or infant death was seen (RR 4.56, 95% CI 
1.00–20.86; 2 trials, 257 babies). Thus, the authors con-
cluded that, in contrast to its effect on neuroprotection, 
magnesium sulfate is ineffective at delaying birth or pre-
venting preterm birth, has no apparent advantages, and 
its use for this indication may be associated with an in-
creased risk of total fetal, neonatal, or infant mortality 
 [11] . Moreover, the FDA recently changed the classifica-
tion of magnesium sulfate from category A to D for con-
cern of fetal and neonatal bone demineralization and 
fractures associated with long-term in utero exposure to 
magnesium sulfate  [12] . Therefore, the FDA advised 
against the use of magnesium sulfate injections for more 
than 5–7 days to stop preterm labor. Finally, the Ameri-
can College of Obstetricians and Gynecologists and the 
Society for Maternal-Fetal Medicine stated in January 
2016 that they still support the short-term use of magne-
sium sulfate for prevention and treatment of seizures in 
women with preeclampsia or eclampsia, fetal neuropro-
tection below 32 weeks, and short-term tocolysis for up 
to 48 h in order to reach the time for fetal lung maturation 
 [13] .
 In this study, an incidence of 7% CMS within 3 weeks 
after fetal surgery was detected in both groups, appar-
ently independent of which tocolytic regimen was used. 
CMS is known to be a significant risk factor for subse-
quent development of PPROM and preterm delivery  [14, 
15] . Johnson et al.  [14] described recently that CMS  ≤ 34 
weeks occurred in 33% and at a mean of 3.6 days after fe-
tal surgery. Only shorter duration of postoperative mag-
nesium sulfate medication (CMS: 21 ± 3.6 h vs. without 
CMS: 22.5 ± 3.2 h) was associated with an increased risk 
of CMS  ≤ 34 weeks, but it was no longer significant after 
adjusting for the respective clinical center  [14] .
 No PPROM within 3 weeks after fetal surgery was 
found in this study. However, in the post-MOMS experi-
ence, 4 neonatal demises were mentioned where women 
had PPROM or preterm labor within 2 weeks of MMC 
repair at 22–24 weeks  [16] . Of these, 2 were previable, in 
1 case, comfort care was provided per parental decision, 
and in 1 case, support was withdrawn due to severe pre-
maturity  [16] . Thus, it is important to prevent PPROM or 
preterm labor by tocolytics as vigorously and as early as 
possible. It has been shown in an experimental study by 
Perrini et al. in 2013  [17] that contractions increase the 
risk of PPROM. They investigated the effect of repeated 
mechanical stretching on the rupture and deformation 
properties of fetal membranes. Already 10 stretching cy-
cles of the fetal membranes, representative of mean phys-
iological contractions, reduced the work to rupture. Sec-
ond harmonic generation microscopy, which is based on 
a nonlinear optical effect and which offers visualization 
of viable cells and their tissue structures and function, 
found that repeated mechanical loading of fetal mem-
branes affected the integrity of the amnion-chorion inter-
face with an altered collagen structure  [18] .
 In conclusion, this study produced evidence that the 
perioperative use of atosiban versus magnesium sulfate 
resulted in a similar short-term uterine outcome. While 
magnesium sulfate was associated with increased and po-
tentially severe maternal complications, atosiban was 
completely free of side effects. These results strongly sug-
gest using atosiban instead of magnesium sulfate in the 
context of open fetal surgery for spina bifida.
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